A Roadmap for Improving the Management of Favorable Risk Prostate Cancer.
暂无分享,去创建一个
David C. Miller | J. Montie | S. Linsell | Andrew Brachulis | B. Lane | M. Cher | Zaojun Ye | G. Auffenberg | N. Rakić
[1] P. Stattin,et al. Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden , 2017, JAMA oncology.
[2] David C. Miller,et al. Calculating life expectancy to inform prostate cancer screening and treatment decisions , 2017, BJU international.
[3] David C. Miller,et al. Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices , 2017, The Journal of urology.
[4] David Gillatt,et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. , 2017, The New England journal of medicine.
[5] H. Lepor,et al. How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United States. , 2016, The Journal of urology.
[6] M. Cooperberg,et al. Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. , 2015, JAMA.
[7] Robert J Volk,et al. Physician variation in management of low-risk prostate cancer: a population-based cohort study. , 2014, JAMA internal medicine.
[8] David C. Miller,et al. Appropriateness Criteria for Active Surveillance of Prostate Cancer , 2017, The Journal of urology.